# A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine

> **NCT04036526** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 50 (estimated)

## Conditions studied

- Whooping Cough

## Interventions

- **BIOLOGICAL:** Vaccine GamLPV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04036526
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-04
- **Primary completion:** 2020-05-29
- **Final completion:** 2020-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04036526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04036526, "A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04036526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*